Apimeds Pharmaceuticals US, Inc. (APUS)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-22

Key Insights

Apimeds failed to file its 2025 Form 10-K on time and received a delisting notice from NYSE American, triggering a six-month cure period ending October 17, 2026 to regain compliance with listing standards.
The company's stock is now trading with a '.LF' (late filer) designation and remains under a trading halt since April 2, 2026, severely limiting liquidity and investor confidence.
Management cited delays in financial statement preparation and independent auditor completion of audit procedures as reasons for the late filing, with an expected filing date of April 30, 2026, but no assurance this deadline will be met.
The company is an emerging growth company with limited financial disclosure obligations, but the delisting risk and extended filing delays raise material concerns about operational capabilities and governance quality.

Current Report Filed: 2026-04-16

Key Insights

Apimeds Pharmaceuticals US, Inc. (APUS) filed a Form 8-K to disclose a delay in filing its annual report on Form 10-K for the fiscal year ended December 31, 2025, primarily due to ongoing financial statement preparation and audit procedures.
The delay in filing the Form 10-K is expected to result in APUS receiving a notice from the NYSE American regarding non-compliance with the applicable continued listing requirements, but the company is working to file the Form 10-K by April 30, 2026.
While APUS is making substantial progress, there is no assurance that the Form 10-K will be filed by the expected date, which could lead to further regulatory and compliance issues if the delay extends beyond the permitted grace period.

Current Report Filed: 2026-03-26

Key Insights

The filing indicates that Inscobee Inc. and Apimeds Korea attempted to remove the board of directors and key executives of Apimeds Pharmaceuticals US, Inc. through an invalid stockholder consent. The company plans to take legal action to enforce its rights under the Merger Agreement.
The company states that the attempted actions by Inscobee and Apimeds Korea constitute a material breach of the Stockholder Support and Lock-Up Agreement, which granted the company an irrevocable proxy over the shares held by these entities.
The company has announced that the current board and executive leadership remain in place, and it does not recognize the alleged appointments made through the invalid stockholder consent.

Current Report Filed: 2026-03-25

Key Insights

The company has removed the previous board of directors, citing concerns over the validity of the representations made regarding MindWave's ownership of certain digital assets and the consummation of the merger.
The company has appointed three new directors, two of which are independent, and has made changes to the executive leadership team, removing the CEO and CFO.
The new directors have professional experience in the biotechnology, engineering, and advertising/real estate industries, which may bring valuable expertise to the company.

Current Report Filed: 2026-03-16

Key Insights

Apimeds Pharmaceuticals US, Inc. (APUS) announced a 1-for-10 reverse stock split, effective on March 26, 2026, which will consolidate the company's outstanding shares and potentially increase the stock price.
The reverse stock split was approved by a majority of APUS shareholders via written consent, indicating broad support for the corporate action.
APUS stock will begin trading on a split-adjusted basis on the NYSE American LLC exchange under the ticker symbol 'APUS' on March 26, 2026, with a new CUSIP number of 03771D201.

Current Report Filed: 2026-01-02

Key Insights

Apimeds Pharmaceuticals US, Inc. has removed Erik Emerson from its board of directors, indicating potential leadership changes within the company.
The removal was effected by a majority vote of the company's stockholders, suggesting shareholder involvement in the decision-making process.
The remaining board members, Elona Kogan, Jakap Koo, Carol O'Donnell, and Dr. Bennett Weintraub, PHD, will continue to guide the company's strategic direction.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.